ArticleBMB reports2014
miR-29a suppresses growth and invasion of gastric cancer cells in vitro by targeting VEGF-A.
Article in BMB reports, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 69 citations in OpenAlex.
- MicroRNA-VEGF axis in gastric cancer: a novel therapeutic frontier.Discover oncology · 2026Review
- miR-29a-3p/Renal failure · 2025Article
- A Comprehensive Cancer-Associated MicroRNA Expression Profiling and Proteomic Analysis of Human Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes.Tissue engineering and regenerative medicine · 2022Article
- The Role of miR-29s in Human Cancers-An Update.Biomedicines · 2022Review
- Modulation of microRNAs and claudin-7 in Caco-2 cell line treated with Blastocystis sp., subtype 3 soluble total antigen.BMC microbiology · 2022Article
- Repurposing Multiple-Molecule Drugs for COVID-19-Associated Acute Respiratory Distress Syndrome and Non-Viral Acute Respiratory Distress Syndrome via a Systems Biology Approach and a DNN-DTI Model Based on Five Drug Design Specifications.International journal of molecular sciences · 2022Article
- The EMT-induced lncRNA NR2F1-AS1 positively modulates NR2F1 expression and drives gastric cancer via miR-29a-3p/VAMP7 axis.Cell death & disease · 2022Article
- MicroRNA miR-29a Inhibits Colon Cancer Progression by Downregulating B7-H3 Expression: Potential Molecular Targets for Colon Cancer Therapy.Molecular biotechnology · 2021Article
- miR-29a-3p inhibits endometrial cancer cell proliferation, migration and invasion by targeting VEGFA/CD C42/PAK1.BMC cancer · 2021Article
- Low expression of miR-29a is associated with aggressive biology and worse survival in gastric cancer.Scientific reports · 2021Article
- Targets and regulation of microRNA-652-3p in homoeostasis and disease.Journal of molecular medicine (Berlin, Germany) · 2021Review
- A Cluster-Based Approach for Identifying Prognostic microRNA Signatures in Digestive System Cancers.International journal of molecular sciences · 2021Article
- miR-29a is a negative regulator of influenza virus infection through targeting of the frizzled 5 receptor.Archives of virology · 2021Article
- Identification of a Novel Prognostic Signature for Gastric Cancer Based on Multiple Level Integration and Global Network Optimization.Frontiers in cell and developmental biology · 2021Article
- Decreased serum exosomal miR-29a expression and its clinical significance in papillary thyroid carcinoma.Journal of clinical laboratory analysis · 2021Article
- [MiR-4443 promotes migration and invasion of breast cancer cells by inhibiting PEBP1 expression].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2020Article
- Long non-coding RNA H19 in atherosclerosis: what role?Molecular medicine (Cambridge, Mass.) · 2020Review
- Expression ofAnnals of translational medicine · 2020Article
- Serum miRNAs, a potential prognosis marker of loco-regionally advanced nasopharyngeal carcinoma patients treated with CCRT.BMC cancer · 2020Article
- miR-17-5p mitigates endometriosis by directly regulating VEGFA.Journal of biosciences · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Increasing data shows miR-29a is a key regulator of oncogenic processes. It is significantly down-regulated in some kind of human tumors and possibly functionally linked to cellular proliferation, survival and migration. However, the mechanism remains unclear. In this study, we report miR-29a is significantly under-expressed in gastric cancer compared to the healthy donor. The microvessel density is negatively related to miR-29a expression in gastric cancer tissues. The ectopic expression of miR-29a significantly inhibits proliferation and invasion of gastric cancer cells. Furthermore, western blot combined with the luciferase reporter assays demonstrate that vascular endothelial growth factor A (VEGF-A) is direct target of miR-29a. This is the first time miR-29a was found to suppress the tumor microvessel density in gastric cancer by targeting VEGF-A. Taken together, these results suggest that miR-29a is a tumor suppressor in gastric cancer. Restoration of miR-29a in gastric cancer may be a promising therapeutic approach.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.